WuXi AppTec Co., Ltd. Stock price

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai Stock Exchange 06:00:00 2023-09-21 pm EDT Intraday chart for WuXi AppTec Co., Ltd. 5-day change 1st Jan Change
79.55 CNY +1.27% +2.04% -1.79%
Sales 2023 * 41,934 M 5,745 M Sales 2024 * 52,785 M 7,232 M Capitalization 233 B 31 899 M
Net income 2023 * 9,904 M 1,357 M Net income 2024 * 12,252 M 1,679 M EV / Sales 2023 *
5,44x
Net cash position 2023 * 4,628 M 634 M Net cash position 2024 * 7,428 M 1,018 M EV / Sales 2024 *
4,27x
P/E ratio 2023 *
23,7x
P/E ratio 2024 *
19,1x
Employees -
Yield 2023 *
1,14%
Yield 2024 *
1,40%
Free-Float65.84%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.05%
1 week+0.76%
Current month-3.62%
1 month+0.96%
3 months+24.09%
6 months-2.13%
Current year-3.02%
More quotes
1 week
78.28
Extreme 78.28
81.62
1 month
75.54
Extreme 75.54
83.45
Current year
61.24
Extreme 61.24
100.00
1 year
61.24
Extreme 61.24
100.00
3 years
61.24
Extreme 61.24
172.49
5 years
29.97
Extreme 29.966
172.49
10 years
11.02
Extreme 11.0204
172.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 Jun. 05
Corporate Officer/Principal 53 Jun. 05
Chief Executive Officer 54 2020
Members of the board TitleAgeSince
Chairman 56 2000
Director/Board Member 54 2020
Director/Board Member 60 2016
More insiders
Date Price Change Volume
23-09-21 79.55 +1.27% 13 698 330
23-09-21 78.55 -2.05% 13,203,350
23-09-20 80.19 -0.26% 9,148,741
23-09-19 80.40 -0.74% 9,143,283
23-09-18 81.00 +1.50% 16,799,100

End-of-day quote Shanghai Stock Exchange, September 20, 2023

More quotes
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
78.55CNY
Average target price
115.24CNY
Spread / Average Target
+46.71%
Consensus
1st Jan change Capi. (M$)
-3.02% 31 863 M $
+36.89% 29 562 M $
-29.15% 25 519 M $
-13.29% 23 838 M $
-14.62% 19 914 M $
+27.28% 11 583 M $
-7.74% 11 151 M $
-5.30% 11 045 M $
+34.54% 6 871 M $
+353.20% 6 559 M $
Bio Therapeutic Drugs
  1. Markets
  2. Equities
  3. Stock WuXi AppTec Co., Ltd. - Shanghai Stock Exchange
-40% off #SeptemberDeals : Our subscriptions help you find hidden investment opportunities.
Subscribe
fermer